Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)]. Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1 pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab-induced uveitis associated with complete or partial tumor response. We suggest that uveitis may serve as a surrogate marker for a tumor response to therapy with pembrolizumab.
Departments of *Oncology ‡Ophthalmology #Dermatology/Allergology **Institute of Immunobiology, Kantonal Hospital St Gallen, St Gallen †Department of Oncology, Hospital Grabs, Grabs §Ludwig Cancer Research Center, University of Lausanne, Lausanne ∥Department of Dermatology ¶Private Ophthalmic Practice in Cooperation with the Skin Cancer Unit, University Hospital of Zurich, Zurich, Switzerland.
Stefan
S
Diem
Fabienne
F
Keller
Reinhard
R
Rüesch
Samia A
SA
Maillard
Daniel E
DE
Speiser
Reinhard
R
Dummer
Marco
M
Siano
Ursula
U
Urner-Bloch
Simone M
SM
Goldinger
Lukas
L
Flatz
D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D015551:Autoimmunity; D060908:CTLA-4 Antigen / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000556:secondary; D016896:Treatment Outcome; D014605:Uveitis / Q000175:diagnosis* / Q000209:etiology
D061067:Antibodies, Monoclonal, Humanized; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab